KOLMAR BNH Co.,Ltd. (KOSDAQ: 200130)

South Korea flag South Korea · Delayed Price · Currency is KRW
12,810
-150 (-1.16%)
Jan 22, 2025, 3:00 PM KST
-23.75%
Market Cap 377.35B
Revenue (ttm) 619.27B
Net Income (ttm) 15.86B
Shares Out 29.12M
EPS (ttm) 544.70
PE Ratio 23.79
Forward PE n/a
Dividend 308.00 (2.38%)
Ex-Dividend Date Dec 27, 2023
Volume 32,111
Average Volume 68,394
Open 12,960
Previous Close 12,960
Day's Range 12,790 - 12,960
52-Week Range 11,030 - 19,970
Beta 0.83
RSI 65.57
Earnings Date Mar 19, 2025

About KOLMAR BNH Co.,Ltd.

Kolmar BNH Co., Ltd. engages in the research and development of materials used in the functional health food and cosmetics market in South Korea and internationally. The company offers cosmetics; and provides total functional health food original development manufacturing services, such as manufacturing tablets, hard capsules, soft capsules, liquids, gels, powder dosage, and various new formulation forms. It offers packaging products, such as PTP/multi-PTP, powder stick/pouch, three-side cloth, four-side, and liquid stick packaging; and ODM con... [Read more]

Industry Perfumes, Cosmetics, and Other Toilet Preparations
Founded 2004
Employees 521
Stock Exchange KOSDAQ
Ticker Symbol 200130
Full Company Profile

Financial Performance

In 2023, KOLMAR BNH Co.,Ltd.'s revenue was 579.55 billion, an increase of 0.63% compared to the previous year's 575.90 billion. Earnings were 19.71 billion, a decrease of -51.35%.

Financial Statements

News

Kolmar BNH Revolutionizes ESG with HemoHIM, an Eco-friendly Health Supplement

SEOUL, South Korea — Kolmar BNH (KRX: 200130), a leading Korean health functional food Original Development Manufacturing (ODM) firm, is at the forefront of Environmental, Social, and Governance (ESG)...

2 months ago - Financial Post

HemoHim Manufacturer Kolmar BNH Receives NAI Classification from the US FDA

SEOUL, South Korea — ‘HemoHim,’ an immune-boosting health supplement from Kolmar BNH (KRX: 200130), has earned international recognition for its quality from both the U.S. Food and Drug Administration...

3 months ago - Financial Post